Ryan Tam

Ryan Tam has worked in a variety of roles in the scientific field since 2013. From 2013 to 2015, they worked as a Research Assistant in the Joseph Wang Research Group, where they synthesized nano-sized helices via electrodeposition and etching to yield magnetic controllable motors, as well as extracted leaf xylem for large scale production of nanomotors. From 2015 to 2016, they worked as a Research Associate at Aridis Pharmaceutical, where they developed excipient formulations for long term storage of dried powders, films, and wet blends of viruses, bacteria, and antibodies, as well as improved efficacy of nebulized drug formulations. From 2016 to 2022, they worked as a Graduate Student Researcher at North Carolina State University, where they constructed a diverse library of deactivated CRISPR Cas9 human epigenome engineering tools to investigate contribution of epigenetics in chronic dopamine-induced phenotypes, characterized novel gene desensitization in human neurons via RNA-sequencing and NGS bioinformatics, and identified optimal parameters for maximal delivery of CRISPR/Cas9 epigenome modifiers in human cells using flow cytometry. Currently, they are a Scientist in Product Development at Tune Therapeutics.

Ryan Tam attended UC San Diego from 2010 to 2015, where they obtained a Bachelor of Science in Nanotechnology. Ryan then went on to pursue a Doctor of Philosophy in Chemical Engineering at North Carolina State University from 2016 to 2022. During this time, they also obtained a Master of Science in Chemical Engineering from North Carolina State University in 2018. Ryan is expected to complete their Doctor of Philosophy in Chemical Engineering from North Carolina State University in December 2022.